Competing endogenous RNA network analysis explores the key IncRNAs, miRNAs, and mRNAs in type 1 diabetes

Chang Li1†, Bo Wei2† and Jianyu Zhao3*

Abstract

Background: Type 1 diabetes (T1D, named insulin-dependent diabetes) has a relatively rapid onset and significantly decreases life expectancy. This study is conducted to reveal the long non-coding RNA (lncRNA)-microRNA (miRNA)-mRNA regulatory axises implicated in T1D.

Methods: The gene expression profile under GSE55100 (GPL570 and GPL8786 datasets; including 12 T1D samples and 10 normal samples for each dataset) was extracted from Gene Expression Omnibus database. Using limma package, the differentially expressed mRNAs (DE-mRNAs), miRNAs (DE-miRNAs), and lncRNAs (DE-lncRNAs) between T1D and normal samples were analyzed. For the DE-mRNAs, the functional terms were enriched by DAVID tool, and the significant pathways were enriched using gene set enrichment analysis. The interactions among DE-lncRNAs, DE-miRNAs and DE-mRNAs were predicted using mirwalk and starbase. The lncRNA-miRNA-mRNA interaction network analysis was visualized by Cytoscape. The key genes in the interaction network were verified by quantitatively real-time PCR.

Results: In comparison to normal samples, 236 DE-mRNAs, 184 DE-lncRNAs, and 45 DE-miRNAs in T1D samples were identified. For the 236 DE-mRNAs, 16 Gene Ontology (GO)_biological process (BP) terms, four GO_cellular component (CC) terms, and 57 significant pathways were enriched. A network involving 36 DE-mRNAs, 8 DE-lncRNAs, and 15 DE-miRNAs was built, such as TRG-AS1—miR-23b/miR-423—PPM1L and GAS5—miR-320a/miR-23b/miR-423—SERPINA1 regulatory axises. Quantitatively real-time PCR successfully validated the expression levels of TRG-AS1—miR-23b—PPM1L and GAS5—miR-320a—SERPINA1.

Conclusion: TRG-AS1—miR-23b—PPM1L and GAS5—miR-320a—SERPINA1 regulatory axises might impact the pathogenesis of T1D.

Keywords: Type 1 diabetes, Long non-coding RNA, mRNA, microRNA, Differential expression analysis, Interaction network

Background

As a metabolic disorder characterized by hyperglycemia, diabetes is induced by secretion deficiency or impaired biological function of insulin [1, 2]. Diabetes can result in impairment and dysfunction of multiple tissues, including heart, blood vessels, eyes, nerves, and kidneys [3–5]. According to the WHO classification of diabetes mellitus in 2019, diabetes are classified as type 1 diabetes (T1D), type 2 diabetes (T2D), hybrid forms of diabetes,
other specific types, such as monogenic diabetes, unclassified diabetes and hyperglycemia first detected during pregnancy [6, 7]. The symptoms of T1D mainly include thirst, polydipsia, polyuria, polyphagia, fatigue, and rapid weight loss [8]. An annual 3%—4% increase in the incidence of T1D in childhood was estimated in several developed countries [9]. Besides, T1D decreases approximately 11–13 years of life expectancy in developed countries, and even more time in developing countries [10]. Quality of life of T1D patients was significantly decreased than general population. Therefore, investigation in the pathogenesis of T1D is warranted to improve the prognosis of T1D patients.

Considerable efforts have been made on the molecular mechanism of T1D during the past decades. The roles of non-coding RNAs, including microRNA (miRNA), long non-coding RNAs (lncRNAs) in the regulation of T1D have only recently been recognized [11]. Through reducing C–C motif chemokine receptor 2 expression, miR-125a-5p limits the migration and function of regulatory T cells (Tregs) in the pancreas of T1D patients [12]. Activity enhancement of miR-181a promotes the expression of nuclear factor of activated T cells 5 (NFAT5) while suppresses the induction of forkhead box P3 + Tregs; therefore, miR-181a/NFAT5 axis may provide targets for limiting islet autoimmunity in T1D patients [13, 14]. The sera level of miR-375 is decreased in T1D patients, indicating that the changed circulating level of miR-375 may be a valuable marker of inflammation and metabolic alterations in T1D [15]. The crosstalk between p38 mitogen-activated protein kinase signaling pathway and the lncRNA metastasis associated lung adenocarcinoma transcript 1 (MALAT1) is correlated with the endothelial cell function in diabetic rats, and MALAT1 inhibition may be a promising approach for anti-angiogenic treatment of diabetic microvascular complications [16]. Besides, lncRNAs MEG3, TUG1 and PVT1 were also being reported to contribute in the pathophysiology of T1D and T1D-associated complications [17–19]. However, only a small part of non-coding RNAs in T1D have been revealed, and more comprehensive understanding of T1D should be developed to facilitate design of preventive therapeutic modalities.

miRNAs can silence gene expression by binding mRNAs, while competing endogenous RNAs (ceRNAs), such as lncRNAs can bind miRNAs via miRNA response elements competitively to regulate gene expression [20, 21]. In this study, the microarray dataset of T1D was searched from Gene Expression Omnibus (GEO) database. Afterwards, differential expression analysis, enrichment analysis, and lncRNA-miRNA-mRNA network (ceRNA network) analysis were executed to investigate the important regulatory axises involved in T1D.

Methods

Data source and data preprocessing

From GEO database (http://www.ncbi.nlm.nih.gov/geo/), the gene expression profile of T1D (accession number: GSE55100, including GPL570 and GPL8786 datasets) was downloaded. This dataset was deposited by Gu et al. [22]. There were 12 peripheral blood mononuclear cell (PBMC) samples from T1D patients and 10 PBMC samples from normal controls in both of GPL570 (including mRNA and lncRNA expression data) and GPL8786 (including miRNA expression data) datasets. The clinical characteristics of the 22 samples were listed in Table 1.

Using the Release 26 (GRCh38.p10) reference genome in GENCODE database (https://www.gencodegenes.org/human/) [23], sequence alignment was conducted. Only the unique alignment sequences were remained. Based on corresponding GTF annotation files, mRNAs (with annotation information of “protein coding”) and lncRNAs (with annotation information of “antisense”, “sense_intronic”, “lincRNA”, “sense_overlapping”, “processed_transcript”, “3prime_overlapping_ncRNA”, and “non_coding”) were identified, respectively. Subsequently, the probes without relevant gene symbols were filtered out. For multiple probes that mapped to one gene symbol, their average value was used as the final expression value of this gene.

Differential expression analysis

For GPL570 and GPL8786 datasets, differential expression analysis between T1D and normal samples were performed using limma package (http://www.bioconductor.org/packages/2.9/bioc/html/limma.html) [24] in R. The corresponding p values of all genes were obtained through statistical test and were conducted with multiple test correction using Benjamini & Hochberg method [25]. The |log fold change (FC)|≥ 0.5 and adjusted p value < 0.05 were considered as the thresholds for obtaining differentially expressed mRNAs (DE-mRNAs).

| Table 1 Clinical characteristics of type 1 diabetes patients |
|-------------------------------------------------------------|
|                | Control | T1D    | p     |
| Female/male    | 6/4     | 5/7    | >0.05 |
| Age, years     | 18.70±1.16 | 17.50±3.68 | >0.05 |
| FBG, mmol/L    | 4.78±0.20 | 6.37±1.93  | <0.05 |
| HbA1C, %       | 5.29±0.42 | 11.78±3.63 | <0.001 |
| GADA, U/mL     | 2.50 (1.87–2.91) | 14985 (47.30–319.33) | <0.01 |
| Fasting C peptide, ng/mL | 2.08±0.77 | 0.47±0.20 | <0.001 |

Values are given as the mean±SD or as median values with the interquartile range in parentheses. T1D, type 1 diabetes; FBG, fasting blood glucose; HbA1C, hemoglobin A1c; GADA, glutamic acid decarboxylase antibody
Meanwhile, the \( p \) value \( \leq 0.05 \) was regarded as the cut-off criterion for selecting differentially expressed miRNAs (DE-miRNAs) and differentially expressed lncRNAs (DE-lncRNAs).

**Enrichment analysis for the DE-mRNAs**

The Gene Ontology (GO) _biological process (BP), GO _molecular function (MF), and GO _cellular component (CC) functional terms involving the DE-mRNAs were analyzed using DAVID tool (version 6.7, https://david-d.ncifcrf.gov/) [26], and the corresponding results were visualized by the R package GOplot (http://cran.r-project.org/web/packages/GOplot) [27]. Using gene set enrichment analysis (GSEA) [28], Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment for the DE-mRNAs was carried out. The adjusted \( p \) value < 0.05 was used for screening the significant results.

**Construction of lncRNA-miRNA-mRNA interaction network**

Using corr.test (parameters: ci = F, adjust = "BH") in R package psych [29], the Pearson correlation coefficients [30] of the expression values of the DE-lncRNAs and the DE-mRNAs were calculated. The lncRNA-mRNA pairs with \( |r| \geq 0.7 \) and adjusted \( p \) value < 0.05 were selected and an lncRNA-mRNA co-expression network was developed. By using Cytoscape software (http://www.cytoscape.org) [31].

Using starbase database (version 3.0, http://starbase.sysu.edu.cn/) [32], lncRNA-miRNA interactions were predicted for the DE-lncRNAs in the lncRNA-mRNA co-expression network. Simultaneously, miRNA-mRNA interactions were predicted for the DE-miRNAs in the lncRNA-mRNA co-expression network by using with mirwalk database (version 3.0, http://mirwalk.umm.uni-heidelberg.de/) [33]. Finally, a lncRNA-miRNA-mRNA interaction network was visualized by Cytoscape software [31]

**Validation of key genes using quantitatively real-time PCR (qRT-PCR)**

T1D patients were recruited from the department of Endocrinology, China-Japan Union Hospital of Jilin University. Age and sex matched healthy controls were recruited from volunteers of physical examination. The experiments were approved by Ethics Committee of China-Japan Union Hospital of Jilin University [No.(2020)linshen(20,201,127)]. Written informed consent was received from all participants. Total RNA were extracted from the PBMCs of T1D patients and normal control samples using RNAiso Plus (TaKaRa, Shiga, Japan). The total RNA was reversed into cDNA with primerScript RT Master Mix (TaKaRa) and amplified on ABI ViiA7 (ThermoFisher, USA). GAPDH was used as the internal reference of DE-lncRNAs and DE-mRNAs and U6 was regarded as the internal reference of DE-miRNAs. The primers were listed in Table 2.

| Table 2 The primers used for qRT-PCR |
|--------------------------------------|
| **Primers**                          | **Sequences (5’–3’)** |
| GASS-hF                              | CACACACGGCATTAGACAGA |
| GASS-hR                              | GCCTCACACAGTGTTAGCTCA |
| TRG-AS1-hF                           | CTCTTCTACTCTCTTAC |
| TRG-AS1-hR                           | TATGATGCGCTAGGTG |
| PPM1L-hF                             | GAGACCCGAGACGGCTTTTCC |
| PPM1L-hR                             | GGCTGACCTCCAGATG |
| SERPINA1-hF                          | ATGCTGCCAGAGACAGATA |
| SERPINA1-hR                          | CTGAAGGCGCACTCAGC |
| hsa-miR-320a-3p-RT                   | GTCGTATCCAGTCGAGGTCGAGTTGTCTTGCACTGAGGACGAGCAGCAGC |
| hsa-miR-320a-3p-F                    | GCCGGTCTCAACCCAGCTTTT |
| hsa-miR-32b-3p-RT                    | GTCGTATCCAGTCGAGGTCGAGTTGTCTTGCACTGAGGACGAGCAGCAGC |
| hsa-miR-32b-3p-F                     | GCCGGTCTCAACCCAGCTTTT |
| hsa-miR-423-5p-RT                    | GTCGTATCCAGTCGAGGTCGAGTTGTCTTGCACTGAGGACGAGCAGCAGC |
| hsa-miR-423-5p-F                     | GCCGGTCTCAACCCAGCTTTT |
| Universal Primer                     | GTGCAGGGTTCGAGG |
| hsa-U6-RT                            | GTGCAGGTTTCGAGG |
| hsa-U6-F                             | GTGCAGGTTTCGAGG |
| hsa-U6-R                             | GTGCAGGTTTCGAGG |

Validation of key genes using quantitatively real-time PCR (qRT-PCR)
Statistical analysis
The data of qRT-PCR was processed by GraphPad Prism 5.0 (San Diego, CA, USA). Data were presented as mean ± standard deviation. Differences between two groups were determined by t-test. P < 0.05 was regarded as statistical significance level.

Results
Differential expression analysis
A total of 1671 mRNAs, 1900 IncRNAs, and 533 miRNAs were identified from the gene expression profile of GSE55100. Compared with normal samples, there were 236 DE-mRNAs (121 up-regulated and 115 down-regulated), 184 DE-IncRNAs (106 up-regulated and 78 down-regulated), and 45 DE-miRNAs (30 up-regulated and 15 down-regulated) in T1D samples (Fig. 1).

Enrichment analysis for the DE-mRNAs
For the 236 DE-mRNAs, 16 GO_BP terms (such as “defense response”, adjusted p value = 5.01E-08; “immune response”, adjusted p value = 1.11E-04; and “response to wounding”, adjusted p value = 3.46E-04) and four GO_CC terms (such as “plasma membrane part”, adjusted p value = 2.72E-02; “intrinsic to plasma membrane”, adjusted p value = 2.90E-02; and “integral to plasma membrane”, adjusted p value = 3.46E-02) were enriched (Table 3).

Meanwhile, 57 significant pathways were enriched for the DE-mRNAs, including 23 activated pathways (normalized enrichment score (NES) > 0; such as “Th1 and th2 cell differentiation”, adjusted p value = 6.56E-03; “T cell receptor signaling pathway”, adjusted p value = 6.56E-03; and “Biosynthesis of unsaturated fatty acids”, adjusted p value = 6.56E-03) and 34 suppressed pathways (NES < 0; such as “Leishmaniasis”, adjusted p value = 6.56E-03; “Legionellosis”, adjusted p value = 6.56E-03; and “Phagosome”, adjusted p value = 6.56E-03) (Table 4).

Construction of IncRNA-miRNA-mRNA interaction network
In the IncRNA-mRNA co-expression network, there were 127 nodes (37 IncRNAs and 90 mRNAs) and 174 edges (Fig. 2). After integrating the results of IncRNA-miRNA interaction prediction and miRNA-mRNA interaction prediction, the IncRNA-miRNA-mRNA interaction network (including 36 mRNAs, 8 IncRNAs, and 15 miRNAs) was constructed (Fig. 3). Importantly, T cell receptor gamma locus antisense RNA 1 (TRG-AS1)—miR-23b/miR-423—protein phosphatase, Mg2+/Mn2+ dependent 1L (PPM1L) and growth arrest specific 5 (GAS5) —miR-320a/miR-23b/miR-423—serpin family A member 1 (SERPINA1) regulatory axises were implicated in the interaction network.

For the mRNAs involved in the interaction network, two GO_BP terms (“Adaptive immune response”, p value = 3.41E-02; “Regulation of immune response”, p value = 4.76E-02), three GO_CC terms (“Endoplasmic reticulum”, p value = 1.78E-02; “Integral component of membrane”, p value = 3.56E-02; “ER to Golgi transport vesicle”, p value = 4.74E-02), one GO_MF term (“Protein homodimerization activity”, p value = 4.78E-02), and one KEGG pathway (“Natural killer cell mediated cytotoxicity”, p value = 1.83E-02) were enriched (Table 5).

Validation of key genes using qRT-PCR
In order to verify the results of bioinformation analysis, the expression of TRG-AS1-miR-23b/miR-423-PPM1L and GAS5-miR-320a/miR-423-SERPINA1 were verified in T1D patients and normal controls. According to the differential expression analysis, TRG-AS1, miR-320a and PPM1L were upregulated in T1D patients, while GAS5, miR-423, miR-23b and SERPINA1 were downregulated in T1D patients. As shown in Fig. 4, the expression levels of TRG-AS1—miR-23b—PPM1L and GAS5—miR-320a—SERPINA1 were consistent with bioinformation analysis (p < 0.05). No significant difference was detected in miR-423 between control group and T1D group (p > 0.05).

Discussion
In recent years, the critical roles of non-coding RNAs including IncRNAs and miRNAs in diabetes were recognized. However, little is known about the molecular mechanism of them in regulating the development of T1D. In this study, 236 DE-mRNAs (121 up-regulated and 115 down-regulated), 184 DE-IncRNAs (106 up-regulated and 78 down-regulated), and 45 DE-miRNAs (30 up-regulated and 15 down-regulated) between T1D samples and normal samples were selected. For the 236 DE-mRNAs, 16 GO_BP terms, four GO_CC terms, and 57 significant pathways were enriched. Moreover, by constructing an IncRNA-miRNA-mRNA co-expression network, two interactions, TRG-AS1—miR-23b/PPM1L and GAS5-miR-320a/miR-423-SERPINA1 regulatory axises were identified.

TRG-AS1 has been reported to be oncogenic in glioblastoma [34], hepatocellular carcinoma [35] and tongue squamous cell carcinoma [36]. It might act as a ceRNA to regulate miRNA-543-Yes-associated protein 1 in tongue squamous cell carcinoma [36], miR-4500-BACH1 in hepatocellular carcinoma [35] and miR-877-5p-SUZ12 in glioblastoma [34]. It also identified to be involved in repeated implantation failure [37]. However, its role in diabetes was not characterized...
Fig. 1 The results of differential expression analysis. a The volcano plot of the differentially expressed mRNAs (DE-mRNAs). b The expression heatmap of the top 10 up-regulated mRNAs and down-regulated mRNAs; c The volcano plot of the differentially expressed lncRNAs (DE-lncRNAs); d The expression heatmap of the top 10 up-regulated lncRNAs and down-regulated lncRNAs; e The volcano plot of the differentially expressed miRNAs (DE-miRNAs); f The expression heatmap of the top 10 up-regulated miRNAs and down-regulated miRNAs. FC, fold change. In volcano plots, red and green separately represent up-regulation and down-regulation. In expression heatmaps, red and blue separately represent type 1 diabetes (T1D) and normal samples.
| Category          | Term                          | Count | Genes                                                                 | Adjusted p value |
|-------------------|-------------------------------|-------|----------------------------------------------------------------------|------------------|
| BP                | GO:0006952 defense response   | 33    | CXCL1, PRF1, KLRC3, TNF, PGLYRP1, CXCR1, CCL5, CCL4, SH2D1A, IFNG, CSF3R, MS4A2, LTF, SERPINA1, CRISP3, IL18RAP, RNASE3, CAMP, GNLY, IL1RN, CHST2, CD160, SAMHD1, SLAMF7, CD180, NCR3, PROK2, TNFAIP6, KLRG1, CCRI, LYST, ALOX5, F2R | 5.01E-08         |
| BP                | GO:0006955 immune response    | 29    | HLA-DQB1, CXCL1, TNF, AQPS, PGLYRP1, CCL5, CCL4, CD96, SH2D1A, IFNG, CEACAM8, LT5, MS4A2, CRISP3, IL18RAP, GZMA, NF4, IL1RN, EOMES, SAMHD1, SLAMF7, CD180, HLA-DQA1, CTSW, NCR3, CST7, ETS1, LYST, TGFBR3 | 1.11E-04         |
| BP                | GO:0009611 response to wounding | 24   | CXCL1, TNF, IL18RAP, IL1RN, CHST2, CXCR1, CCL5, CCL4, CD180, NCR3, PROK2, TNFAIP6, KLRG1, CD46, DYSF, AD5, LTF, MS4A2, SIRPB1, CD96, CDC42, IL12RB1, DYSF, GZMA, IL18RAP, RNASE3, RNASE1, RNASE3, CAMP, GNLY, IL1RN, CHST2, CD160, SAMHD1, SLAMF7, CD180, HLA-DQA1, CTSW, NCR3, CST7, ETS1, LYST, TGFBR3 | 3.46E-04         |
| BP                | GO:0006954 inflammatory response | 18  | CXCL1, TNF, IL18RAP, IL1RN, CHST2, CXCR1, CCL5, CCL4, CD180, NCR3, PROK2, TNFAIP6, KLRG1, CD46, DYSF, AD5, LTF, MS4A2, SIRPB1, CD96, CDC42, IL12RB1, DYSF, GZMA, IL18RAP, RNASE3, RNASE1, RNASE3, CAMP, GNLY, IL1RN, CHST2, CD160, SAMHD1, SLAMF7, CD180, HLA-DQA1, CTSW, NCR3, CST7, ETS1, LYST, TGFBR3 | 6.96E-04         |
| BP                | GO:0006968 cellular defense response | 8    | PRF1, SH2D1A, KLRC3, KLRC1, CCR3, GNLY, CD160, CCL5 | 5.26E-03         |
| BP                | GO:0008285 negative regulation of cell proliferation | 17  | CEBA, COL18A1, CXCL1, TNF, PTPRM, ZBTB16, SKAP2, ADM, ETS1, IFNG, GZMB, GZMA, TNFAIP6, PROK2, KLRG1, CCR3, GNLY, CD160, CCL5, CCL4, CD180, NCR3, PROK2, TNFAIP6, KLRG1, CD46, DYSF, AD5, LTF, MS4A2, SIRPB1, CD96, CDC42, IL12RB1, DYSF, GZMA, IL18RAP, RNASE3, RNASE1, RNASE3, CAMP, GNLY, IL1RN, CHST2, CD160, SAMHD1, SLAMF7, CD180, HLA-DQA1, CTSW, NCR3, CST7, ETS1, LYST, TGFBR3 | 7.51E-03         |
| BP                | GO:0009617 response to bacterium | 12   | TNF, RNASE3, ADM, LYT, CAMP, GNLY, IFNG, PGLYRP1, LTF, SERPINA1, CCL5, F2R | 1.31E-02         |
| BP                | GO:0002703 regulation of leukocyte-mediated immunity | 7    | SH2D1A, TBX21, IFNG, MS4A2, CD226, LG3, NCR3 | 2.83E-02         |
| BP                | GO:0019835 cytolysis | 5    | GZMM, PRF1, GZMA, GZMB, GZMH | 3.10E-02         |
| BP                | GO:0051270 regulation of cell motion | 11  | COL18A1, PTPRM, ETS1, SMAA7, MIP9, RRS2, TGFBR3, JAK2, ARAP3, IGBP3, F2R | 3.59E-02         |
| BP                | GO:0031434 positive regulation of cell killing | 5    | SH2D1A, IFNG, CD226, LG3, NCR3 | 3.87E-02         |
| BP                | GO:0030099 myeloid cell differentiation | 8    | CEBA, CDC42, TNF, MMP9, TGFBR3, JAK2, ZBTB16, FLVCR1 | 3.92E-02         |
| BP                | GO:0042127 regulation of cell proliferation | 24  | CEBA, COL18A1, CXCL1, TNF, PTPRM, ZBTB16, SKAP2, HHEX, IL12RB1, ADM, ETS1, IFNG, GZMB, GZMA, TNFAIP6, PROK2, KLRG1, CCR3, GNLY, CD160, CCL5, CCL4, CD180, NCR3, PROK2, TNFAIP6, KLRG1, CD46, DYSF, AD5, LTF, MS4A2, SIRPB1, CD96, CDC42, IL12RB1, DYSF, GZMA, IL18RAP, RNASE3, RNASE1, RNASE3, CAMP, GNLY, IL1RN, CHST2, CD160, SAMHD1, SLAMF7, CD180, HLA-DQA1, CTSW, NCR3, CST7, ETS1, LYST, TGFBR3, JAK2, ARAP3, IGBP3, F2R | 4.15E-02         |
| BP                | GO:0002697 regulation of immune effector process | 8    | SH2D1A, TNF, TBX21, IFNG, MS4A2, CD226, LG3, NCR3 | 4.63E-02         |
| BP                | GO:0030334 regulation of cell migration | 10   | COL18A1, PTPRM, SMAA7, MIP9, RRS2, TGFBR3, JAK2, ARAP3, IGBP3, F2R | 4.74E-02         |
| BP                | GO:0031341 regulation of cell killing | 5    | SH2D1A, IFNG, CD226, LG3, NCR3 | 4.89E-02         |
| CC                | GO:0044459 plasma membrane part | 48   | HLA-DQB1, KCNJ15, TNF, AQPS, APH1A, FFAR2, CD247, KCNJ2, SIRPB1, CD96, CDC42, IL12RB1, DYSF, CEACAM8, CSF3R, MS4A2, CSF2RB, DLGS, KLRF1, NRG1, KLRD1, LAG3, CSF2RA, FLVCR1, IL2RB, PTPRM, STX3, CD3G, SMAD7, GZMA, NF4, SYT11, PTP4N, CD160, ABCB1, GZMA, HLA-DQA1, NCR3, TNFRSF10C, NPC1, CCR3, RRAS2, TGFBR3, JAK2, RS9, NKG7, CD226, F2R | 2.72E-02         |
| CC                | GO:0031226 intrinsic to plasma membrane | 31   | KCNJ15, TNF, AQPS, APH1A, FFAR2, KCNJ2, SIRPB1, CD96, IL12RB1, CEACAM8, CSF3R, MS4A2, CSF2RB, KLRF1, CSF2RA, FLVCR1, IL2RB, CD3G, PTPRM, SYT11, NCF4, CD160, HLA-DQA1, NCR3, NPC1, TNFRSF10C, CCR3, TGFBR3, NKG7, CD226, F2R | 2.90E-02         |
| CC                | GO:0005887 integral to plasma membrane | 30   | KCNJ15, TNF, AQPS, APH1A, FFAR2, KCNJ2, SIRPB1, CD96, IL12RB1, CEACAM8, MS4A2, CSF2RB, CSF3R, KLRF1, CSF2RA, FLVCR1, IL2RB, CD3G, PTPRM, SYT11, NCF4, CD160, HLA-DQA1, NCR3, NPC1, TNFRSF10C, CCR3, TGFBR3, NKG7, CD226, F2R | 3.46E-02         |
| CC                | GO:0005886 plasma membrane | 72   | KCNJ15, AQPS, CXCR1, SKAP2, LG6R, SIRPB1, CDC42, CD96, DYSF, CEACAM8, OSCAR, S1PR5, SMAGP, CSF2RB, MS4A2, CSF3R, DLGS, NRG1, KLRD1, CSF2RA, LG3, FLVCR1, KLRB1, STX3, CD3G, PTPRM, SYT11, DYSF, CEACAM8, OSCAR, S1PR5, SMAGP, CSF2RB, MS4A2, CSF3R, DLGS, NRG1, KLRD1, CSF2RA, LG3, FLVCR1, KLRB1, STX3, CD3G, PTPRM, SYT11, NCF4, CD160, SIGLEC10, GZMA, BASP1, HLA-DQA1, NCR3, NPC1, TNFRSF10C, CCR3, TGFBR3, NKG7, CD226, F2R | 3.88E-02         |

**BP**: biological process; **CC**: cellular component
### Table 4 The activated pathways and suppressed pathways enriched for the differentially expressed mRNAs (top 10 listed)

| Description                                      | Normalized enrichment score | Genes                                                                 | Adjusted p value |
|--------------------------------------------------|-----------------------------|----------------------------------------------------------------------|------------------|
| **Up-regulated pathways**                        |                             |                                                                      |                  |
| Natural killer cell mediated cytotoxicity         | 1.88803                     | KLRC3, KLRC1, IFNG, GZMB, PRF1, NCR3, SH2D1A, CD247, NCR1, FASLG, PIK3R3, PPP3CC, CD244, HCST, ZAP70, KLRC4, FYN, KIR2DL1, PIK3R1, PLCG1, LCX, KIR3DL1, LAT | 6.56E-03         |
| Biosynthesis of unsaturated fatty acids           | 1.989893                    | ELOVL6, ACOT7, TECR/ACOT4, SCDS, FADS2                                | 6.56E-03         |
| T cell receptor signaling pathway                 | 2.006524                    | IFNG, CD3G, CD62, CD247, PTTPRC, CD8A, PIK3R3, PPP3CC, MAPK13, CD3D, PRICK4, AKT3, ITK, ZAP70, RASGRF1, FYN, GRAP2, PIK3R3, POP1, PLCG1, NAPIC3, PIK3R9, LCX, LAT, NCK2 | 6.56E-03         |
| TH1 and TH2 cell differentiation                  | 2.137425                    | IFNG, CD3G, RUNX3, TBX21, STAP4, IL12RB1, CD247, PPP3CC, MAPK13, CD3D, PRICK4, ZAP70, GATA3, PLCG1, NAPIC3, IL12RB2, IL2RG, PIK3R9, LCX, LAT, Dll1, NAMM3 | 6.56E-03         |
| RNA degradation                                   | 1.717539                    | PFKP, MPHOSPH6, PAPD5, HSPA9, DDX6, EXOSC2, LMS2, LMS3, TOB1, DCP1B, LMS3, TOB1, EXOSC7, LSM2, LSM5, TOB1, DCP1B, | 8.48E-03         |
| Ribosome biogenesis in eukaryotes                 | 1.778302                    | LSG1, WDR9, AK6, WDR43, RIKO1, POP5, EMO1, RPP40, RAN, EEF1, NXL2, PAP5, RAP58, GNL3L, NVL, GNL3L, GNL3L, NVL, GNL3L, | 8.48E-03         |
| TH17 cell differentiation                         | 1.854181                    | IFNG, RORA, CD3G, IL2RB, IL12RB1, CD247, PPP3CC, MAPK13, CD3D, RPRC, ZAP70, GATA3, PLCG1, NAPIC3, IL12RB2, IL2RG, PIK3R9, LCX, LAT, Dll1, NAMM3 | 8.48E-03         |
| Proteasome                                        | 1.88607                     | IFNG, PSMD11, PSMD14, PSMB9, PSMD6, PSMA3, PSMB2, PSMA1, PSMA5, PSMA7, PSMB10, PSMB4, PSME1, PSMB6, PSMB2, PSMD2, PSMB8, PSMB4, PSMB5, PSME3, PSMD12, PSMA2, PSMB1 | 8.48E-03         |
| Graft versus host disease                         | 1.87728                     | KLRD1, IFNG, GZMB, PRF1, FASLG, KIR2DL1                                | 8.97E-03         |
| Fatty acid elongation                              | 1.857462                    | ELOVL6, ACOT7, TECR, ACOT4, ELOVL7, ACA2                                | 1.14E-02         |
| **Down-regulated pathways**                       |                             |                                                                      |                  |
| Leishmaniasis                                     | — 1.90122                   | MYD88, PTPN6, JAK1, ITGB1, CYBB, IL1A, TLR2, IRAK1, NCF2, TAB2, NCF1, IFNGR2, CR1, NCF4, TAK2, TNF, PTPG2, FCGR3B    | 6.56E-03         |
| Legionellosis                                      | — 1.89969                    | NLRCA, CD14, CASP1, EEF1A2, TLR2, IL18, EEF1A1, HSPD1, APAF1, CR1, CRXCL8, TNF, HSPA6, CRXCL1 | 6.56E-03         |
| Phagosome                                         | — 1.86804                    | TUBA1C, TUBA1A, THB51, C3, CORO1A, ATP6V1C1, RAB5C, ITGB1, HGS, TUBB1, ATP6V1B2, CD36, TUB53, ATP6V0B, FCGR2B, MRCl1, TUB22A, CD14, ATP6V0C, TUB54, CYBB, RAB7A, TLR2, CLEC7A, ATP6V1A, ATP6V0D1, NCF2, TLR6, NCF1, FCAR, LAMP1, CTS1, NCF4, OLRI, FCGR3B, MPO | 6.56E-03         |
| Hematopoietic cell lineage                        | — 1.7603                     | FCER2, CD10D, CD22, CD1C1, CD4, CD37, CR2, CD19, CSF1R, IL3RA, CD36, IL11RA, CD14, IL9, IL1A, ANPEP, M5A4, CD19, CD1, IL1R1, CSF2RA, CD59, MME, TNF, CSF3R, IL1R2, CD24 | 6.56E-03         |
| Tuberculosis                                      | — 1.74971                    | RAB5A, MAPK10, TLR9, RFXAP, RAB5B, FCER1G, IFNA7, SPH2, CLEC4A, SYK, RAF1, ATTP6AP1, CALML5, MAPK9, C3, FADD, MYD88, CEIDPB, CORO1A, JAK1, RAB5C, CREBI, IL10RB, KSR1, LSP1, NOD2, ATP6V0B, FCGR2B, SPH1K1, BCI10, MRC1, NFYC, IFNA17, CD14, CAMK2G, ATP6V0C, RAB7A, IL1A, TLR2, IL18, CLEC7A, EP300, TLR1, ATP6V0D1, IRAK1, CTS1, TLR6, HSPD1, IFNGR2, RHOA, LAMP1, APAF1, CR1, CTS1, JAK2, TNF, FCGR3B, CAMP | 6.56E-03         |
| Protein digestion and absorption                  | — 1.70571                    | COL27A1, SLC6A19, SLC8A1, SLC7A7, KCNQ1, CELA3, PRSS5, COL5A3, COL1A2, ATP1B1, COL9A4, SLC7A8, COL9A2, COL17A1, KCN3, COL5A3, COL1A1, MM1E, CPA3 | 6.56E-03         |
| Cytokine cytokine receptor interaction            | — 1.48441                    | CCR10, IL3RA, IL17RA, TNFSF13, IL19, CCL8, EGRF, IL11RA, OSM, CXXL12, CXXR5, IFNLR1, TNFRSF18, IL17RC, PRL, IFNA17, PLEKHO2, IL9R, IL17RB, IL1RAF5, IL1A, IL18, HGF, VEGFA, CCR6, IFNGR2, TNFSF10, PF4V1, CCL8, CCL20, TNFSF8, IL1R1, CSF2RA, CCL2, CCR9, CSF2RB, TNF, TNFRSF10C, CXXCR1, CSF3R, CXXL1, IL1R2, TNFRSF17, CCR3 | 6.56E-03         |
| Starch and sucrose metabolism                     | — 1.89049                    | GBE1, G6PC2, GPI, GAA, HK3, G6PC3, PGAM2L1, ENPP3, PYGL, MGAM | 8.48E-03         |
| Glycine serine and threonine metabolism           | — 1.80927                    | GAMT, PGAM2, AOC3, BPGM, AOC2, ALAS1, GLDC, ALAS2 | 8.48E-03         |
| Amoebiasis                                        | — 1.70409                    | PRKACA, RAB5C, SERPINC10, LAMB2, LAMB3, GNAQ, COL1A2, CD14, PLCB2, RAB7A, TLR, LAMAS5, ACTN1, CCL8, IL1R1, TNF, CTSG, CXXL1, IL1R2, ARG1 | 8.48E-03         |
previously. In our study, we predicted the miRNAs and mRNAs that might be regulated by TRG-AS1. The lncRNA-miRNA-mRNA network displayed that it could directly regulate 5 miRNAs including miR-423 and miR-23b, and multiple mRNAs, including PPM1L indirectly. MiR-23b/27b expression is decreased in the muscle stem cells of T2D patients, which exerts a pro-myogenic function via the p53 pathway [38]. Nuclear factor, erythroid 2/miR-423-5p axis can induce gluconeogenesis and hyperglycemia through inhibiting the family with sequence similarity 3 member A -adenosine triphosphate (ATP)-serine/threonine kinase Akt pathway, which is involved in the progression of T2D and nonalcoholic fatty liver disease [39]. Increased miR-320 impairs lipid metabolism and gluconeogenesis by targeting adiponectin receptor 1 (AdipoR1), and thus miR-320 may be taken as a possible target for T2D therapy [40]. The elevated levels of the T lymphocytes expressing gamma-delta T cell receptor are implicated in the islet autoimmune process in individuals at high risk of T1D, which may serve as a promising indicator for the development of T1D [41, 42]. PPM1L mediates inositol-requiring protein-1 phosphorylation and endoplasmic reticulum stress signaling, which is considered as a causal gene for metabolic abnormalities [43]. The macrophage-enriched network has a causal correlation with metabolic disease traits, which involved three obesity genes (including PPM1L) [44]. Therefore, we hypothesized that TRG-AS1 and PPM1L might also play roles in the mechanisms of T1D through the TRG-AS1—miR-23b/miR-423—PPM1L regulatory axis.

GAS5 is a member of 5’ terminal oligopyrimidine class which could regulate cell growth, proliferation, and survival [45]. Reduced serum levels of GAS5 are related to diabetes; therefore, serum GAS5 levels combined with other parameters may be used for identifying people at high risk of diabetes more accurately [46]. Shi et al. demonstrated that GAS5 regulates insulin signaling in adipocytes, and suggested it might be a potential target for T2DM [47]. GAS5 knockdown causes cell cycle arrest and impairs insulin synthesis and secretion in Min6 pancreatic β-cells, and thus GAS5 may function in maintaining the identity and function of β cells [48]. In this study, GAS5 was found decreased in T1D patients in both RNA-seq results and the qRT-PCR results, which is consistent with previous studies. We found GAS5 could regulate 7 miRNAs, including miR-320a, miR-23b and miR-423, and tens of mRNAs, including SERPINA1 in T1D. MiR-320 negatively mediates the expression of fibronectin, endothelin 1, and vascular endothelial growth factor via extracellular signal-regulated kinases 1 and 2 in
high glucose-treated human umbilical vein endothelial cells, which may provide a novel approach for treating diabetic complications [49]. Wei et al. found miR-320 mimic correlated with impaired gluconeogenesis and lipid metabolism by regulating adipoR1 [40]. SERPINA1 is a serine protease inhibitor that could target elastase, plasmin, thrombin, trypsin, chymotrypsin, and plasminogen activator. It was shown to be decreased in serum of obese mice and human subjects and the imbalance between SERPINA1 and neutrophil elastase contributed to insulin resistance [50]. Lower levels of SERPINA1 selectively impaired the ATP-binding cassette transporter A1 cholesterol efflux capacity in T2D [51]. Other members in this family were also reported to participate in development of diabetes. Anti-SERPINE1 antibody contributes to Reg gene expression and beta cell proliferation, and the immunological response may hinder the progression of T1D [52]. The serum concentrations of SERPINA12 (vaspin) is increased in T2D patients, which may be a candidate marker for evaluating the risk of severe macrovascular complications and the status of old T2D patients [53]. Thus, GAS5—miR-320a/miR-23b/miR-423—SERPINA1 regulatory axis might also function in the pathogenesis of T1D.

![Fig. 3](image-url) The long non-coding RNA (lncRNA)-miRNA-mRNA interaction network. Red, yellow, and blue circles represent mRNAs, lncRNAs, and miRNAs, respectively.

| Category | ID    | Description                      | p value    |
|----------|-------|----------------------------------|------------|
| BP       | GO:0002250 | Adaptive immune response         | 3.41E-02   |
| BP       | GO:00050776 | Regulation of immune response    | 4.76E-02   |
| CC       | GO:0005783 | Endoplasmic reticulum            | 1.78E-02   |
| CC       | GO:0016021 | Integral component of membrane   | 3.56E-02   |
| CC       | GO:0030134 | ER to Golgi transport vesicle    | 4.74E-02   |
| MF       | GO:0042803 | Protein homodimerization activity| 4.78E-02   |
| Pathway  | hsa04650   | Natural killer cell mediated cytotoxicity | 1.83E-02 |

**Table 5 The Gene Ontology (GO) functional terms and pathways enriched for the mRNAs involved in the long non-coding RNA (lncRNA)-miRNA-mRNA interaction network**

BP: biological process; CC, cellular component; MF, molecular function.
Conclusion
In conclusion, 236 DE-mRNAs, 184 DE-lncRNAs, and 45 DE-miRNAs between T1D and normal samples were identified. Besides, TRG-AS1—miR-23b/miR-423—PPM1L and GAS5—miR-320a/miR-23b/miR-423—SERPINA1 regulatory axes might be related to the pathogenesis of T1D. Though we have validated the expression of these genes in T1D patients, further mechanically mechanism of these regulatory axes should be investigated by subsequent studies.

Abbreviations
T1D: Type 1 diabetes; lncRNA: Long non-coding RNA; mRNA: MicroRNA; DEMiRNA: Differentially expressed miRNAs; GO: Gene Ontology; BP: Biological process; CC: Cellular component; T2D: Type 2 diabetes; Tregs: Regulatory T cells; NFAT5: Nuclear factor of activated T cells 5; MALAT1: Metastasis Associated Lung Adenocarcinoma Transcript 1; ceRNAs: Competing endogenous RNAs; GEO: Gene Expression Omnibus; PBMC: Peripheral blood mononuclear cell; FC: Fold change; KEGG: Kyoto Encyclopedia of Genes and Genomes; qRT-PCR: Quantitatively real-time PCR; NES: Normalized enrichment score; TRG-AS1: T cell receptor gamma locus antisense RNA 1; PPM1L: Protein Phosphatase Mg2+/Mn2+ Dependent 1 L; GAS5: Growth arrest specific 5; SERPINA1: Serpin family A member 1; ATP: Adenosine triphosphate; AdipoR1: Adiponectin Receptor 1.

Acknowledgements
None.

Authors’ contributions
CL and BW analyzed and interpreted the RNA-sequencing data. JYZ designed the study, collected the patients and performed the experiments. CL was a major contributor in writing the manuscript. BW and JYZ revised the manuscript. All authors read and approved the final manuscript.

Funding
None.

Availability of data and materials
The dataset analysed during the current study are available in the GEO repository with accession number of GSE53110 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE53110), GPL570 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GPL570), GPL8786 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc/GPL8786). The reference genome of Release 26 (GRCh38, p10) is available in GENCODE database (https://www.gencodegenes.org/human/). The interactions between IncRNA and miRNAs were obtained from starbase (http://starbase.sysu.edu.cn/). The miRNA-mRNA interactions were obtained from mirwalk database (http://mirwalk.umm.uni-heidelberg.de/).

Ethics approval and consent to participate
The experiments were approved by Ethics Committee of China-Japan Union Hospital of Jilin University (No.(2020)linshen(20201127)). Written informed consent was received from all participants. No participant under the age of 16 was involved in the validation set.

Consent for publication
Not applicable.

Competing interests
All authors declare no conflicts of interest in this paper.

Author details
1 Departments of VIP Unit, China-Japan Union Hospital of Jilin University, Changchun 130033, Jilin, China. 2 Departments of Neurosurgery, China-Japan Union Hospital of Jilin University, Changchun 130033, Jilin, China. 3 Department of Endocrinology, China-Japan Union Hospital of Jilin University, 126 Xiantai Street, Changchun 130033, Jilin, China.

Received: 20 February 2020 Accepted: 14 January 2021

Published online: 01 February 2021

References
1. Puchulu FM. Definition, diagnosis and classification of diabetes mellitus. Diabetes Care. 2018;33(Suppl 1):S62–9.
2. El-Sappagh S, Elmogy M, Ali F, Kwak KS. A case-base fuzzification process: diabetes diagnosis case study. Soft Comput. 2018;9:815–34.
3. Dong Y, Fernandes C, Liu Y, Wu Y, Wu H, Brophy ML, Deng L, Song K, Wen A, Wong S. Role of endoplasmic reticulum stress signalling in diabetic endothelial dysfunction and atherosclerosis. Diabetes Vasc Dis Res. 2017;14(1):14–23.
4. Feinleib I, Winterer G, Pischon T. Diabetes is associated with risk of post-operative cognitive dysfunction: A meta-analysis. Diabetes/Metab Res Rev. 2017;33(5):e2884.
5. Mihardja L, Delima D, Massie RGA, Karyana M, Nugroho P, Yunir E. Prevalence of kidney dysfunction in diabetes mellitus and associated risk factors among productive age Indonesian. J Diabetes Metab Disord. 2018;17(4):53–61.
6. Rossi G, Association AD. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2018;33(Suppl 1):S62–9.
7. Classification of diabetes mellitus. https://www.who.int/publications-item/classification-of-diabetes-mellitus. Accessed 2 Dec 2020.
8. Lundgren M, Jonsdottir S, Larsson HE, Group FS. Effect of screening for type 1 diabetes on early metabolic control: the Diabetes in Primary Care Study. Diabetologia. 2018;62(1):53–7.
9. Patterson CC, DaHquist GG, Gyuris E, Green A, Soltesz G. Incidence trends for childhood type 1 diabetes in Europe during 1989–2003 and predicted new cases 2005–20: a multicentre prospective registration study. Lancet. 2009;373(9680):2027–33.
10. Livingstone SJ, Levin D, Looker HC, Lindsay RS, Wild SH, Joss N, Leese G, Leslie P, McCreinnon RJ, Metcalfe W et al. Estimated life
expectancy in a scottish cohort with type 1 diabetes, 2008–2010. JAMA. 2015;313(1):37–44.

10. Tahan M, Eghtedarian R, Dinger ME, Ghafoori-Fard S. Emerging roles of non-coding RNAs in the pathogenesis of type 1 diabetes mellitus. Biomed Pharmacother. 2020;129:110508.

11. Sebastiani G, Vertiniglia G, Stabilini A, Socci C, Morisciani C, Laurenza A, Nigi L, Formichi C, Mafarej B, Petrelli A. Regulatory T-cells from pancreatic lymph-nodes of patients with type-1 diabetes express increased levels of micro-RNA miR-125a-5p that limits CC2R expression. Sci Rep. 2017;7(1):6897.

12. Serri, Scherm MG, Zahm AM, Schug J, Flynn VK, Hippich M, Kallen S, Becker M, Achenbach P, Nikolaev A. miR-15a/16-1/NEAT5 axis links impaired T cell tolerance induction with autoimmune type 1 diabetes. Sci Transl Med. 2018;10(422):eaqz782.

13. Nabil ES, Andrawes NG. The association between circulating levels of miR-181a-1 and pancreatic beta cells dysfunction via SMAAD7 in type 1 diabetic children and adolescents. J Clin Lab Anal. 2016;30(5):272–31.

14. Marchand L, Jalabert A, Meugnier E, Hende KVD, Fabien N, Nicolino M, Madec AA, Thivoli C, Rome S. miRNA-375 a sensor of glucotoxicity is altered in the serum of children with newly diagnosed type 1 diabetes. J Diabetes Res. 2016;2016:1869082.

15. Liu JY, Yao J, Li XM, Song YC, Wang QX, Li YJ, Yan B, Jiang Q. Pathogenic role of IncRNA-MALAT1 in endothelial cell dysfunction in diabetes mellitus. Cell Death Dis. 2014;5(10):e1506.

16. Wang N, Zhi X, Zhang W, Li JF, Yu Y, Yuan Q, De W. Long Noncoding RNA Meg3 regulates mafa expression in mouse beta cells by inactivating Rad21, Smc3 or Sin3a. Cell Physiol Biochem. 2018;44(5):2031–43.

17. Krishnan P, Syed F, Jiyun Kang N, Mirrma RG, Evans-Molina C. Profiling of RNAs from human islet-derived exosomes in a model of type 1 diabetes. Int J Mol Sci. 2019;20(23):5903.

18. Li Z, Hao S, Yin H, Gao J, Yang Z. Autophagy ameliorates cognitive impairment through activation of PV1T and apoptosis in diabetes mice. Behav Brain Res. 2016;305:265–77.

19. Kartha RV, Subramanian S. Competing endogenous RNAs (ceRNAs): new entrants to the intricacies of gene regulation. Front Genet. 2014;5(06):8.

20. Wu J, Li M, Zhong H, Hu C. Competing endogenous RNA in cancer: a new pattern of gene expression regulation. Int J Clin Exp Med. 2015;8(10):17110–17.

21. Yang M, Ye L, Wang B, Gao J, Liu R, Hong J, Wang W, Gu W, Ning G. Decreased miR-146 expression in peripheral blood mononuclear cells is correlated with ongoing islet autoimmunity in type 1 diabetes patients with age >146. J Diabetes. 2015;7(2):158–65.

22. Harow J, Frankish A, Gonzalez JM, Tapanari E, Diekhans M, Kokocinski F, Aken BL, Barrell D, Zadissa A, Searle S. GENCODE: The reference Splice Graph and gene model annotation for The ENCODE Project. Genome Res. 2012;22(9):1760–73.

23. Ritche ME, Belinda P, D W, Yifang H, Law CW, Wei S, Smyth GK. Imma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.

24. Sotani A, Goeman J. Minimally adaptive BH: A tiny but uniform improvement of the procedure of Benjamini and Hochberg. Biometrical J. Biometrische Zeitschrift. 2017;59(4):776–80.

25. da Huang W, Sherman BT, Lempicki RA. Systematic and integrative analysis of biological networks. Methods Mol Biol. 2011;696:291–303.

26. Feng B, Chakrabarti S. miR-320 regulates glucose-induced gene expression utilizing isof orm-specific expression. Genet Epidemiol. 2017;41(6):498–510.

27. Jason M. Psych issues. JEMS. 2013;38(3):14.

28. Schober P, Boer C, Schwarte LA. Correlation coefficients: appropriate use and interpretation. Anesth Analg. 2018;126(5):1763–8.

29. Kohl M, Wiese S, Warscheid B. Cytoescape: software for visualization and analysis of biological networks. Methods Mol Biol. 2011;696:291–303.

30. Yang JH, Li JH, Shao P, Zhou H, Chen YQ, Qu LH. starBase: a database for exploring microRNA-mRNA interaction maps from Argonauta CLIP-Seq and Degradome-Seq data. Nucleic Acids Res. 2011;39(Database issue):D202–9.

31. Dweep H, Gretz N. mirWalk2.0: a comprehensive atlas of microRNA-target interactions. Nat Methods. 2015;12(8):697.